Pharmacokinetic (PK) Evaluation of Nalmefene Formulations

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is designed to characterize the PK of nalmefene following IV bolus and IMinjections using nalmefene 0.5 mg (0.94% MgCl2) and IV bolus of 0.5 mg nalmefenehydrochloride injection in healthy subjects.
Epistemonikos ID: cc1e5c64de26ef22cbdc70f7111c9eb0f5a629ab
First added on: Apr 22, 2026